Skip to main content

CORRECTION article

Front. Oncol., 25 October 2021
Sec. Gastrointestinal Cancers: Colorectal Cancer
Volume 11 - 2021 | https://doi.org/10.3389/fonc.2021.792453

Corrigendum: The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer

This article is a correction to:

  1. The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer

    1. Read original article
Tinghui Duan&#x;Tinghui Duan1†Diyuan Zhou&#x;Diyuan Zhou2†Yizhou Yao*Yizhou Yao2*Xinyu Shao*Xinyu Shao3*
  • 1Department of Medical Imaging, The Affiliated Guangji Hospital of Soochow University, Suzhou, China
  • 2Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China
  • 3Department of Gastroenterology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China

A Corrigendum on:
The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer

by Duan T, Zhou D, Yao Y and Shao X (2021) Front. Oncol. 11:706838. doi: 10.3389/fonc.2021.706838

In the original article, there was a mistake in Figure 7B as published. We identified a minor error in image-misusing was made. The corrected Figure 7 appears below.

FIGURE 7
www.frontiersin.org

Figure 7 FGF1 promotes proliferation and migration ability of CRC cells. (A, B) Colony formation capacity (A) and migration rates (B) of FGF1-KD CRC cells. CRC, colorectal cancer. (C) Wound healing assays were carried out at 24h after transfection in 6-well plates. The gap width was measured using Open Lab software. (D) The wound rate was calculated and displayed graphically according to the measured results by Open Lab software. NC, negative control; KD, FGF1-shRNA. Data are presented as mean ± SD (n=3). Ns, no significance, *P < 0.05.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: colorectal cancer, FGF1, mTOR-S6K1 pathway, prognosis, survival

Citation: Duan T, Zhou D, Yao Y and Shao X (2021) Corrigendum: The Association of Aberrant Expression of FGF1 and mTOR-S6K1 in Colorectal Cancer. Front. Oncol. 11:792453. doi: 10.3389/fonc.2021.792453

Received: 10 October 2021; Accepted: 11 October 2021;
Published: 25 October 2021.

Edited and reviewed by:

Alessandro Passardi, Romagnolo Scientific Institute for the Study and Treatment of Tumors (IRCCS), Italy

Copyright © 2021 Duan, Zhou, Yao and Shao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Xinyu Shao, xinxinyuxin0711@163.com; Yizhou Yao, yzyao@suda.edu.cn

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.